Nuwellis Expands Pediatric Reach with Aquadex SmartFlow Installations in Wisconsin
Event summary
- Nuwellis installed its first Aquadex SmartFlow® systems at a leading pediatric healthcare institution in Wisconsin on July 28, 2026.
- The installation marks the company's expansion into a new pediatric market, targeting critical care settings.
- Nuwellis anticipates submitting a 510(k) application to the FDA by the end of 2026 for an expanded label to include pediatric patients weighing 5 kilograms and above.
The big picture
Nuwellis' expansion into Wisconsin underscores its strategic focus on pediatric and critical care settings, where precise fluid management is increasingly recognized. The move aligns with broader industry trends toward specialized therapies for critically ill children, positioning Nuwellis to strengthen its leadership in the cardiorenal space. Success hinges on regulatory approval and clinical adoption.
What we're watching
- Regulatory Approval
- The pace at which Nuwellis secures FDA approval for the expanded pediatric label will determine its ability to tap into a broader patient population.
- Market Adoption
- Whether Nuwellis can establish clinical protocols and workflows in Wisconsin that support broader utilization of Aquadex therapy over time.
- Competitive Positioning
- How Nuwellis will differentiate itself in the pediatric critical care market as it competes with other fluid management solutions.